Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 17/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | PPARG | P37231 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.64 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.64 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.64 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.64 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19029193 | 0.93 | HDAC6 (1.00) | HDAC6KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL19029170 | 0.88 | HDAC6 (0.77) | HDAC6KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL21352482 | 0.80 | HDAC6 (0.81) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL19028972 | 0.80 | HDAC6 (1.00) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL19029183 | 0.80 | HDAC6 (1.00) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL19029422 | 0.80 | HDAC6 (0.71) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL1675536 | 0.80 | HDAC6 (0.77) | HDAC6KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL19029203 | 0.79 | HDAC6 (0.95) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL19029271 | 0.79 | HDAC6 (0.81) | HDAC6MAPTHDAC3HDAC1HDAC2 | |
| SCHEMBL19029159 | 0.79 | HDAC6 (0.79) | HDAC6HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108602812-B | Bicyclic hydroxamic acids useful as inhibitors of histone deacetylase activity in mammals | 坎塞拉有限公司 | 2021-11-02 | — | — | CN | claimed |
| EP-3394052-B1 | BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | KANCERA AB (SE) | 2021-07-28 | — | — | EP | claimed |
| US-10654814-B2 | Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity | KANCERA AB (SE) | 2020-05-19 | — | — | US | claimed |
| US-20190284147-A1 | BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | KANCERA AB (SE) | 2019-09-19 | — | — | US | claimed |
| EP-3394052-A1 | BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | Kancera AB (SE) | 2018-10-31 | — | — | EP | claimed |
| WO-2017108282-A1 | BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | KANCERA AB (SE) | 2017-06-29 | — | — | WO | claimed |
| CN-108602812-B | Bicyclic hydroxamic acids useful as inhibitors of histone deacetylase activity in mammals | 坎塞拉有限公司 | 2021-11-02 | — | — | CN | disclosed |
| EP-3394052-B1 | BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | KANCERA AB (SE) | 2021-07-28 | — | — | EP | disclosed |
| EP-3394052-B1 | BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | KANCERA AB (SE) | 2021-07-28 | — | — | EP | disclosed |
| US-10654814-B2 | Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity | KANCERA AB (SE) | 2020-05-19 | — | — | US | disclosed |
| US-10654814-B2 | Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity | KANCERA AB (SE) | 2020-05-19 | — | — | US | disclosed |
| US-20190284147-A1 | BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | KANCERA AB (SE) | 2019-09-19 | — | — | US | disclosed |
| US-20190284147-A1 | BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | KANCERA AB (SE) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654814-B2 | Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity | HDAC1, HDAC11, HDAC10 | HDAC6 10/4885KDM4E 1411/4885ALDH1A1 1264/4885 |
| US-20190284147-A1 | BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | HDAC1, HDAC11, HDAC10 | HDAC6 10/4885KDM4E 1411/4885ALDH1A1 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.